The effect of referral to an open‐group behavioural weight‐management programme on the relative risk of normoglycaemia, non‐diabetic hyperglycaemia and type 2 diabetes: Secondary analysis of the WRAP trial by Ahern, AL et al.
OR I G I N A L A R T I C L E
The effect of referral to an open-group behavioural weight-
management programme on the relative risk of
normoglycaemia, non-diabetic hyperglycaemia and type 2
diabetes: Secondary analysis of the WRAP trial
Amy L. Ahern PhD1 | Simon J. Griffin DM1,2 | Graham M. Wheeler PhD3 |
Stephen J. Sharp MSc1 | Paul Aveyard PhD4 | Emma J. Boyland PhD5 |
Jason C. G. Halford PhD5 | Susan A. Jebb PhD4
1MRC Epidemiology Unit, University of
Cambridge School of Clinical Medicine,
Cambridge, UK
2Primary Care Unit, University of Cambridge
School of Clinical Medicine, Cambridge, UK
3Cancer Research UK & UCL Cancer Trials
Centre, University College London,
London, UK
4Nuffield Department of Primary Care Health
Sciences, University of Oxford, Oxford, UK
5School of Psychology, University of Liverpool,
Liverpool, UK
Correspondence
Amy L. Ahern, MRC Epidemiology Unit, Box
285 Institute of Metabolic Sciences, University
of Cambridge, Cambridge, CB2 0QQ.
Email: ala34@cam.ac.uk
Funding information
Medical Research Council, Grant/Award
Numbers: MC_UU_12015/4, U105960389,
MR/J000493/1; National Institute for Health
Research, RP-PG0216-20010
Peer Review
The peer review history for this article is
available at https://publons.com/publon/10.
1111/dom.14123.
Abstract
Aim: To examine the impact of open-group behavioural weight-management
programmes on the risk of diabetes among those with a body mass index (BMI) of
≥28 kg/m2 and those with non-diabetic hyperglycaemia (NDH).
Methods: This was a secondary analysis of data from the WRAP trial, in which partic-
ipants (N = 1267; aged ≥18 years, BMI ≥ 28 kg/m2) were randomized to brief inter-
vention (BI; self-help booklet), a weight-management programme (WW; formerly
Weight Watchers) for 12 weeks, or WW for 52 weeks. We used multinomial logistic
regression to examine the effect of intervention group on the risk of hyperglycaemia
and diabetes at 12 months in all participants with glycaemic status at both time
points (N = 480; 38%) and those with NDH at baseline (N = 387; 31%). We used
mixed effects models and linear fixed effects models to examine the effect of inter-
vention group on body weight and HbA1c at 12 months in people with NDH.
Results: There was a 61% relative reduction in the risk of NDH at the 12-month fol-
low-up (12 weeks vs. BI: relative risk ratio [RRR] = 0.39 [95% CI 0.18, 0.87], P = .021;
52 weeks vs. BI: RRR = 0.38 [95% CI 0.17, 0.86], P = .020). For intervention effects
on the risk of diabetes, confidence intervals were wide and overlapped 1 [12 weeks
vs. BI: RRR = 0.49 [95% CI 0.12, 1.96], P = .312; 52 weeks vs. BI: RRR = 0.40 [95% CI
0.10, 1.63], P = .199). Participants with hyperglycaemia at baseline in the weight-
management programme were more probable to have normoglycaemia at the 12-
month follow-up [12-week programme vs. BI: RRR = 3.57 [95% CI 1.24, 10.29],
P = .019; 52-week programme vs. BI: RRR = 4.14 [95% CI 1.42, 12.12], P = .009).
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Conclusions: Open-group behavioural weight-management programmes can help to
prevent the development of NDH in people with overweight and obesity and to nor-
malize glycaemia in people with NDH.
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1 | INTRODUCTION
Large randomized controlled trials (RCTs) have shown that intensive
behavioural programmes can reduce or delay the incidence of type 2
diabetes (T2D) by 30%-60% in people with non-diabetic hyper-
glycaemia (NDH) identified by screening using repeated oral glucose
tolerance tests (OGTTs).1 However, population screening using
OGTTs would represent a significant burden to patients and health
service staff and put pressure on existing resources.2 More pragmatic
screening tests, such as HbA1c, have been recommended,2,3 but these
would still be expensive if conducted with sufficient frequency to
identify the large numbers of people developing hyperglycaemia each
year. Excess weight is a strong predictor of T2D4 and identifying indi-
viduals at risk of T2D on the basis of body mass index (BMI) may be a
less expensive and simpler approach.5 Diabetes prevention
programmes that only include people with BMI ≥25 kg/m2 show a
50% greater reduction in the risk of T2D than those programmes that
also enrol people with a lower BMI.6 However, to date, no studies of
diabetes prevention programmes have used excess weight as the sole
inclusion criterion.
Intensive behavioural programmes evaluated in diabetes preven-
tion trials can only be offered to a fraction of those with hyper-
glycaemia because they are expensive to run and the necessary
specialized workforce is scarce. A recent systematic review found that
less intensive behavioural programmes in routine healthcare or com-
munity settings achieved a 26% reduction in T2D risk, and a lower
average weight loss of 2.6 kg (compared with a 58% risk reduction
and 6 kg weight loss in the US Diabetes Prevention Programme).7
However, this review only included programmes with the specified
aim of reducing diabetes incidence and excluded most behavioural
programmes that focus on weight loss, despite both types of pro-
gramme encouraging very similar changes in diet and physical activity
using similar behavioural strategies. Commercial open-group behav-
ioural weight-management programmes, such as WW (formerly
Weight Watchers) and Slimming World, are some of the most com-
monly commissioned weight-management treatments in the UK, have
evidence of effectiveness from RCTs and are less expensive than most
diabetes prevention programmes.8–11 However, there is little direct
evidence of the impact of these generic weight loss programmes on
the risk of developing hyperglycaemia or diabetes, or on the reversion
of people with diabetes or NDH to NDH or normoglycaemia.
Two recent studies have evaluated the effectiveness of referral
to WW combined with a specific diabetes prevention education ses-
sion among people with NDH. In a US RCT, this combined
intervention achieved greater weight loss (5.5% vs. 0.2%, P < .001)
and greater reductions in HbA1c (−0.22% vs. −0.14%; P = .032) at
12 months compared with a diabetes education counselling session
and self-help materials developed by the US Diabetes Education Pro-
gram.12 In an uncontrolled study of a similar combined intervention in
the UK National Health Service (NHS), a reduction in mean weight of
10 kg and in HbA1c of 2.8 mmol/mol was observed at 12 months
using an intention to treat analysis.13 However, no studies have exam-
ined the impact of the standard WW programme among people with
NDH, or the effect of such programmes on the risk of T2D in individ-
uals recruited on the basis of BMI alone.
In the WRAP trial (Weight loss Referrals for Adults in Primary
care), 1267 adults identified by their primary care physician as having
a BMI of ≥28 kg/m2 were randomized to one of three weight loss
interventions: brief intervention, a 12-week referral to a commercial
open-group weight-management programme (WW) or a 52-week
referral to the same programme.9 Participants referred to the
programmes lost more weight than those in the brief intervention.
The 52-week programme was associated with greater reductions in
weight, HbA1c and fasting blood glucose than the 12-week pro-
gramme and the brief intervention. Here, we use data from the WRAP
trial to examine the effect that referral to an open-group behavioural
programme has on the probability of hyperglycaemia and T2D after
1 year among adults. We also quantify the effects on glycaemia in the
subsample of participants with hyperglycaemia at baseline.
2 | METHODS
2.1 | Study design
The full protocol (including measures and assays) and primary analyses
from the WRAP trial have been published elsewhere.9,14 In brief,
this was a multicentre, non-blinded, parallel groups trial with uneven
randomization. Participants were adults aged ≥18 years, with
BMI ≥28 kg/m2, identified via a search of electronic primary care
records and invited to participate by mail. We randomized 1267 eligi-
ble participants to one of three weight-management interventions in a
2:5:5 ratio: brief intervention, 12 weeks of an open-group behavioural
programme (WW) or 52 weeks of the same behavioural programme.
Participants attended measurement appointments at the research
centre or their local GP practice at baseline and at 12 months. The
trial is registered at Current Controlled Trials (ISRCTN82857232).
Given the focus of this trial on the impact of programme duration on
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weight loss, we did not originally declare the incidence of hyper-
glycaemia or diabetes as outcomes.
2.2 | Interventions
Participants in the brief intervention group received a printed booklet
of self-help weight-management strategies from the British Heart
Foundation. Participants in the behavioural programmes were given
vouchers to attend weekly WW meetings and to use WW web-based
tools for the duration of the intervention (12 or 52 weeks). The WW
intervention provides advice, support and encouragement to lose
weight and then maintain any loss, and uses a range of evidence-
based behavioural change techniques to support changes to a lower
energy diet and increases in physical activity.
2.3 | Outcomes
The primary outcome of the WRAP trial was body weight and this
was measured at each time point. Participants were also asked to
report medication use in the previous 3 months. Other cardiovascular
risk factors, including plasma glucose, HbA1c and lipid profile, were
measured via a fasting blood sample at baseline and 12 months, which
was optional for participants. For participants who provided a blood
sample, we categorized participants as having normoglycaemia, NDH
or T2D at baseline and 12 months using American Diabetes Associa-
tion criteria for HbA1c (39-47 mmol/mol = NDH; ≥48 mmol/mol = dia-
betes) and fasting glucose (5.6-6.9 mmol/mol = NDH; ≥7 mmol/
mol = diabetes), and the use of diabetes medication.15
2.4 | Statistical analysis
To examine whether the intervention group was associated with the
risk of diabetes or hyperglycaemia (relative to normoglycaemia) at
12 months (primary analysis), we used multinomial logistic regression
and adjusted for baseline glycaemic category, baseline weight, age,
research centre and sex. Effect sizes were reported as relative risk
ratios (RRRs), for example, the risk ratio of diabetes (relative to nor-
moglycaemia) comparing 12 weeks versus brief intervention. We con-
ducted two sensitivity analyses. The first sensitivity analysis excluded
participants for whom use of metformin was the only criteria for dia-
betes categorization, because metformin has indications other than
diabetes. The second sensitivity analysis used World Health Organiza-
tion (WHO) criteria to categorize glycaemic status (for HbA1c: 42-
47 mmol/mol = NDH, ≥48 mmol/mol = diabetes; for fasting glucose:
6.1-6.9 mmol/mol = NDH, ≥7 mmol/mol = diabetes).16
To evaluate the effect of the three interventions among partici-
pants who had NDH at baseline, we examined the differences
between groups in mean change from baseline to 12 months for
weight, fasting glucose and HbA1c. We undertook a missing at ran-
dom analysis using a variance components model; we imputed 50
datasets using a multiple imputation with chained equations (MICE)
approach, as the joint distribution of target variables did not appear to
come from a multivariate normal distribution. The imputation model
regressed the target variable on centre and imputation was stratified
by treatment group. We then calculated mean (SE) change in the tar-
get variable from the imputed datasets. For analyses of weight
change, we fit a multivariate mixed effects model using generalized
least squares to each imputed dataset with intervention group, time
point, intervention group by time point interaction and centre as fixed
effects. Random intercepts were permitted for each participant.
Results were then combined across all imputed datasets using Rubin's
rules.17 For analysis of fasting glucose and HbA1c levels, data were
available for baseline and 12 months. We therefore used linear regres-
sion on the imputed datasets to estimate treatment effects, with tar-
get variable at 12 months as the outcome, with adjustments made for
baseline value, centre and intervention group.
To examine whether intervention group was associated with
glycaemic status category at 12 months in people with NDH at base-
line, we used the same multinomial logistic regression method
described above in the subsample of WRAP participants who were
categorized as having NDH at baseline.
Analyses were performed using Stata version 14.2.18
3 | RESULTS
We ascertained glycaemic status at baseline for 879 participants, and
at both baseline and 12 months for 480 participants.
The primary analysis included the 480 participants with glycaemic
status at both time points. Characteristics of these participants are
shown in Table 1. This subset of participants had a slightly higher
mean age (difference in means = 5.92; 95% CI 4.39, 7.44 years) and a
larger proportion of men (38% vs. 28%) than members of the trial
population who were not eligible for inclusion in this analysis, but
there was no evidence of a difference in baseline weight.
Participants referred to the 12- and 52-week programmes were
less probable than those in the brief intervention group to be catego-
rized as having NDH compared with normoglycaemia at 12 months
(12-week programme vs. brief intervention: RRR = 0.39 [95% CI 0.18,
0.87], P = .021; 52-week programme vs. brief intervention: RRR =
0.38 [95% CI 0.17, 0.86], P = .020) (Figure 1A). Although the point
estimates of the RRR suggested that participants in the 12- and 52-
week programmes are less probable to have diabetes at 12 months,
the confidence intervals were wide and compatible with both a nega-
tive and positive association (12-week programme vs. brief interven-
tion: RRR = 0.49 [95% CI 0.12, 1.96], P = .312; 52-week programme
vs. brief intervention: RRR = 0.40 [95% CI 0.10, 1.63], P = .199) (Fig-
ure 1B). Table 2 shows the frequency of changes from one diabetes
status category to another by intervention group.
A sensitivity analysis, which excluded participants who were tak-
ing metformin but whose HbA1c levels were within the normal range,
showed similar results. Sensitivity analyses using WHO criteria for
NDH showed no evidence of a difference between groups for risk of
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NDH (12-week programme vs. brief intervention: RRR = 0.63 [95% CI
0.25, 1.61], P = .338; 52-week programme vs. brief intervention:
RRR = 0.58 [95% CI 0.23, 1.50], P = .262) and diabetes (12-week pro-
gramme vs. brief intervention: RRR = 0.79 [95% CI 0.20, 3.10],
P = .736; 52-week programme vs. brief intervention: RRR = 0.63 [95%
CI 0.16, 2.51], P = .510) at 12 months.
At baseline, 387 participants (46%) had HbA1c levels within the
NDH category (brief intervention, N = 66; 12-week programme,
N = 173; 52-week programme, N = 148). Baseline characteristics of
these participants are shown in Table 1. Changes in weight, fasting
glucose and HbA1c between baseline and 12 months are shown by
intervention group in Table 3. Participants in the 12- and 52-week
programme groups lost more weight than the brief intervention group
after 12 months (12-week programme vs. brief intervention: −3.00 kg
[95% CI −5.05, −0.94], P = .0044; 52-week programme vs brief inter-
vention: −4.27 kg [95% CI −6.43, −2.10], P = .0001). There was no
evidence of a difference between the 52-week and the 12-week pro-
gramme (−1.27 kg [95% CI −2.76, 0.22], P = .0958). There were mean
reductions in HbA1c and fasting blood glucose at 12 months in all
groups (Table 3), but no evidence of differences between the groups.
Using WHO criteria for HbA1c and fasting glucose to categorize
glycaemic status, 156 participants had NDH at baseline. Sensitivity
analysis using WHO criteria showed very similar results, but there
was a larger difference in weight loss between the 12- and 52-week
programmes at 12 months.T
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RRR (95% CI)
12 weeks vs. BI 0.39 (0.18,0.87)
52 weeks vs. BI 0.38 (0.17, 0.86)
0.1 1 10
RRR (95% CI)
12 weeks vs. BI 0.49 (0.12,1.96)
52 weeks vs. BI 0.40 (0.10, 1.63)
0.1 1 10
(A)
(B)
F IGURE 1 (A) Relative risk ratios (RRRs) for non-diabetic
hyperglycaemia at 12 months: 12- and 52-week behavioural
programmes compared with brief intervention (BI), adjusted for
baseline glycaemic status, baseline age, baseline weight, sex and
centre. (B) RRRs for diabetes at 12 months: 12- and 52-week
behavioural programmes compared with BI, adjusted for baseline
glycaemic status, baseline age, baseline weight, sex and centre
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Participants with NDH referred to the 12- and 52-week
programmes were more probable than those in the brief intervention
group to have reverted to normoglycaemia at 12 months (12-week
programme vs. brief intervention: RRR = 3.57 [95% CI 1.24, 10.29],
P = .019; 52-week programme vs. brief intervention: RRR = 4.14 [95%
CI 1.42, 12.12], P = .009) (Figure 2A). There was little evidence to sug-
gest that those referred to these programmes were less probable to
have diabetes at 12 months as confidence intervals were wide and
overlapped 1 (12-week programme vs. brief intervention: RRR = 0.90
[95% CI 0.15, 5.33], P = .905; 52-week programme vs. brief interven-
tion: RRR = 0.25 [95% CI 0.02, 3.04], P = .279) (Figure 2B).
4 | DISCUSSION
In this secondary analysis of data from the WRAP trial, we found that
participants with overweight or obesity who were randomized to an
open-group behavioural weight-management programme were 61%
less probable to have NDH at 12-month follow-up than participants
allocated to a brief intervention. Few people were categorized as hav-
ing diabetes at the 12-month follow-up (N = 7, 1%), which reduced
our ability to detect differences between groups in T2D incidence,
and there was no evidence of a difference between groups in diabetes
status at this time point. Among participants with NDH at baseline,
participants in the behavioural weight-management programmes were
more probable to have normoglycaemia at 12 months than those who
received brief intervention (self-help materials).
This study is limited by the comparatively small proportion of
WRAP trial participants who provided blood samples at baseline and
follow-up and could be included in the analyses. However, no differ-
ences were identified between these participants and the entire
WRAP sample. Blood samples were only collected at baseline and
12 months. In contrast to the original explanatory diabetes prevention
trials, few studies of pragmatic programmes have followed partici-
pants beyond 1 year. Nevertheless, this short follow-up meant that
only a small proportion of participants developed diabetes, which
reduced study power. The study is also limited by the use of a single
measure of HbA1c, glucose and/or medication to classify NDH and
diabetes. Given the focus of this trial on the impact of programme
duration on weight loss, we did not originally declare the incidence of
hyperglycaemia or diabetes as outcomes. The strengths of the study
include the randomized trial design and the recruitment of a commu-
nity-based sample with minimal exclusion criteria that is broadly gen-
eralizable to the UK population. While men where under-represented,
there was a higher proportion (32%) of men in this trial than typically
found in trials of weight-management interventions and there was no
evidence that sex moderated the effect of the intervention.9 Over half
of the participating practices were in areas with a high index of multi-
ple deprivation.19
Overweight and obesity is one of the strongest risk factors for
T2D4 and weight loss is the principal target of diabetes prevention
programmes.7,20 However, the dominant paradigm for diabetes pre-
vention is identification of individuals at high risk (defined as those
with NDH) via population screening, and referral to a specialist diabe-
tes prevention programme. This study shows that delivering a behav-
ioural weight-management programme to all people with overweight
and obesity could be an effective approach to diabetes prevention,
with a 60% reduction in the risk of NDH at 12-month follow-up. The
reduction in the risk of diabetes was of a similar magnitude, but the
width of the confidence intervals suggests that this evidence is weak.
TABLE 2 Frequency table of glycaemic status at baseline and 12 months by intervention group
Glycaemic status
Baseline Normo NDH Diabetes
12 months Normo NDH Diabetes Normo NDH Diabetes Normo NDH Diabetes
Treatment group Brief intervention 16 (84%) 3 (16%) 0 (0%) 5 (16%) 25 (78%) 2 (6%) 2 (11%) 2 (11%) 15 (79%)
12-week programme 63 (93%) 5 (7%) 0 (0%) 39 (39%) 56 (57%) 4 (4%) 2 (5%) 7 (16%) 34 (79%)
52-week programme 67 (92%) 6 (8%) 0 (0%) 37 (43%) 48 (56%) 1 (1%) 0 (0%) 9 (22%) 32 (78%)
Abbreviations: NDH, non-diabetic hyperglycaemia; normo, normoglycaemia.
RRR (95% CI)
12 weeks vs. BI 3.57 (1.24, 10.29)
52 weeks vs. BI 4.14 (1.42, 12.12)
0.1 1 10 100
RRR (95% CI)
12 weeks vs. BI 0.90 (0.15, 5.33)
52 weeks vs. BI 0.25 (0.02, 3.04)
0.01 0.1 1 10
(A)
(B)
F IGURE 2 (A) Relative risk ratios (RRRs) for normoglycaemia at
12 months in participants with non-diabetic hyperglycaemia at baseline:
12- and 52-week behavioural programmes compared with brief
intervention (BI), adjusted for baseline weight, age, sex and centre. (B)
RRRs for diabetes at 12 months in participants with non-diabetic
hyperglycaemia at baseline: 12- and 52-week behavioural programmes
compared with BI, adjusted for baseline weight, age, sex and centre
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In a population-based cohort of 30 000 middle-aged people (aged
30–60 years at baseline), we showed that over a 10-year period, mod-
erate weight loss (3%-7%), could prevent two in every five cases of
T2D.5 Using BMI to identify high-risk individuals is less expensive and
more feasible than population-level testing of blood glucose and could
identify people earlier in the disease trajectory, thereby preventing
progression to NDH. This is important because glycaemia has an
approximately linear association with cardiovascular events and mor-
tality.21,22 Consequently, Rose's prevention paradox may apply,23
such that more heart attacks will be prevented by shifting the overall
population distribution of BMI and glycaemia than by targeting scarce
resources at the minority at highest risk. If the focus of diabetes pre-
vention shifted to those with excess weight, commonly commissioned
weight-management programmes could be readily incorporated into
diabetes prevention policy. We have previously estimated that the
12-week programme, which costs ~£55 per person, is a more cost-
effective intervention than the 52-week programme at ~£190 per per-
son,9 but these are both lower than the estimated average cost of UK
NHS diabetes prevention programmes (£270 per person).8 The large
open-groups, rolling curriculum format, and variety of times and loca-
tions of meetings mean that people can start at any time, choose a
time and location which suits them, and that key information is
repeated if they miss any sessions. This greater flexibility than the
closed-group sessions typically used in diabetes prevention
programmes may increase attendance and adherence. This study also
showed for the first time that a stand-alone open-group behavioural
weight-management programme is a potentially effective option to
reduce the risk of diabetes in people with NDH. When we restricted
the eligible population to participants with NDH at baseline, we
showed that the behavioural weight-management programme led to
slightly greater weight loss than that reported in a meta-analysis of
pragmatic diabetes prevention programmes.6 However, our results
are similar to findings from a US trial, which compared attendance at
Weight Watchers meetings combined with a diabetes education ses-
sion with a US National Diabetes Education Program individual
counselling session and self-help materials.12 Reductions in HbA1c
were larger than the pooled mean in the meta-analysis of prag-
matic interventions to prevent diabetes,6 and similar to a US trial
of a commercial programme adapted to prevent diabetes.12 How-
ever, the confidence intervals around the estimate of this effect in
our study were large and crossed zero, probably because of the
comparatively small sample/group size in the current study. Taken
together with evidence from a similar combined intervention in a
scheme running in the UK NHS, which observed a mean reduction
in weight of 10 kg and in HbA1c of 2.8 mmol/mol13 among people
with NDH in primary care, these findings suggest that this open-
group behavioural weight-management programme has comparable
effectiveness with dedicated diabetes prevention programmes in
people with NDH, and could be incorporated into diabetes preven-
tion pathways. It is unclear whether the education/activation ses-
sion incorporated in the US trial and UK NHS models adds value,
but it is clear that the weight-management programme itself is a
crucial component.T
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The weight losses and reductions in glycaemia are smaller than
those offered by bariatric surgery or formula diet meal replace-
ments,24,25 but are clinically meaningful and comparable with inten-
sive, specialist-led diabetes prevention programmes.6,7,20 Offering
these programmes to all people with overweight and obesity would
support people early in the disease trajectory and reduce the risk of
NDH as well as diabetes. The weight loss achieved through these
programmes also has other physical and mental health benefits.26
However, where limited resources necessitate a focus on people who
already have NDH, these programmes still offer an effective
approach. Commercial versions of these programmes already have the
existing infrastructure to enable (inter)national rollout and there is evi-
dence that they can be incorporated into existing models of weight
management and diabetes prevention.
In conclusion, among people known to have hyperglycaemia, a
stand-alone open-group behavioural weight-management programme
leads to successful weight loss and reductions in glycaemia which
appear comparable with specialist diabetes prevention programmes.
Identifying individuals at risk of diabetes on the basis of BMI alone
and offering them a widely available weight-management programme
might be a more pragmatic, scalable and efficient diabetes prevention
strategy than screening for hyperglycaemia and referral to specialist
programmes, and might facilitate intervention earlier in the disease
trajectory.
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